Pelthos Therapeutics Inc. (PTHS) intrinsic value & 10-year financials
Pelthos Therapeutics Inc. (PTHS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 5 fiscal years revenue reached to $16.8M, with an average return on invested capital of -18.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $20.15
- Market cap
- $37.9M
- Revenue (FY2025)
- $16.8M
- ROIC (10-yr avg)
- -18.3%
- Free cash flow (FY2025)
- -$22.7M
PTHS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $16.8M | -$43.3M | -$23.04 | -$22.7M | -193.1% | -271.2% |
| FY2024 | $0 | -$8.0M | -$1.43 | — | — | 234.6% |
| FY2023 | — | -$7.4M | -$5.78 | — | — | — |
| FY2022 | — | -$2.5M | — | — | — | — |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Pelthos Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Pelthos Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -0.2% ROIC.
Pelthos Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Pelthos Therapeutics Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.